Select Page

Corporate Symposium


THURSDAY | 02/08/18

Corporate Symposium Biometrix/One Lambda - room Segovia I and II

12:45 – 13:45

  • AllType™ NGS Workflow: A complete and flexible solution for High Resolution HLA typing with Ion-S5 and Illumina-Miseq Platforms
    Speaker: Harry Lopez
  • Setting up NGS for HLA typing utilizing Kits ALLType™ NGS –Experience of a Brazilian lab
    Speaker: Mônica Goldenstein
Corporate Symposium AMGEN

12:45 – 13:45 – Role of MRD and Immunotherapy in Optimizing ALL Treatment Outcomes

Speaker: Peter Bader
Moderator: Nelson Hamerschlak

12:45 – 13:05 – Optimizing transplant outcomes in ALL – the role of immunotherapy
Speaker: Peter Bader

13:05 – 13:20 – Management of MRD positive in ALL
Speaker: Peter Bader

13:20 – 13:35 – Clinical Case Discussion
Speaker: Peter Bader

13:35 – 13:45 – Discussion

Corporate Symposium JANSSEN

12:45 – 13:45 – cGVHD: a new treatment era

12:45-13:25 – Presentation
Speakers: Afonso Celso Vigorito and Mary Evelyn Flowers

13:25-13:35 – Discussion of Clinical Cases
Speakers: Afonso Celso Vigorito and Mary Evelyn Flowers

13:35-13:45 – Questions and Answers Session
Speakers: Afonso Celso Vigorito and Mary Evelyn Flowers

Corporate Symposium CELGENE

12:45 – 13:45 – Consolidation and maintenance after SCT in Multiple Myeloma patients

Speakers: Roberto Magalhães and Jayr Schimidt Filho
Moderator: Marcelo Pasquini

12:45 – Introduction

12h50 – Lecture 1 – Rational for maintenance after SCT in multiple myeloma
Speaker: Roberto Magalhães

13:05 – Lecture 2 – Use of lenalidomide maintenance in multiple myeloma after SCT
Speaker: Jayr Schimidt Filho

13:20 – Clinical cases discussion – round table

13:45 – Closing remarks

FRIDAY | 03/08/18

Corporate Symposium NOVARTIS

12:45 – 13:45 – Corporate Symposium NOVARTIS: Breaking down barriers in the treatment of GVHD with ruxolitinib

Speakers: Celso Arrais and Aliana Ferreira

12:45 – 12:55 – GVHD in Brazil

12:55 – 13:35 – The experience of treating GVHD with ruxolitinib

13:35 – 13:45 – Questions

Corporate Symposium AMGEN

12:45 – 13:45 – Second-generation Proteasome inhibitors (PIs), an important ally for hematopoietic stem cell transplantation (HSCT)

Moderator: Ângelo Maiolino

  • 12:45 – 13:00 – Relevance of Proteasome Inhibitors in Multiple Myeloma treatment
    Speaker: Ângelo Maiolino
  • 13:00 – 13:30 – Second-generation Proteasome inhibitors, a bridge to HSCT
    Speaker: Garles Vieira
Corporate Symposium TAKEDA

12:45 – 13:45 – Evidence and Experience in the treatment of R/R HL

Moderator: Vanderson Rocha

  • Long-term strategies to optimize the results for patients with R/R HL
    Speaker: Samir Nabhan Kanaan
  • Clinical experience with consolidation therapy in R/R HL
    Speaker: Marco Aurélio Salvino
Corporate Symposium Zodiac

12:45 – 13:45 – VOD/SOS: Sharing Experience in Diagnosis Criteria and Treatment

12:45 – 12:50 – Opening
Speaker: Nelson Hamerschlak

12:50 – 13:30 – VOD Diagnosis and treatment
Speaker: Wael Saber

13:30 – 13:40 – Clinical Case
Speaker: Adriana Seber

13:40 – 13:45 – Questions & Answers
Speakers: All

REALIZAÇÃO

ORGANIZAÇÃO

PRATA

BRONZE

APOIO INSTITUCIONAL

 

TRANSPORTADORA OFICIAL